7.4.2. targeted therapies. sporadic ccrcc, hif accumulation due vhl-inactivation results overexpression vegf platelet-derived growth factor (pdgf), promote neo-angiogenesis [531-533]. process substantially contributes development progression rcc. several targeting drugs treatment mrcc approved usa europe. published trials selected clear-cell carcinoma subtypes, thus robust evidencebased recommendations given non-ccrcc subtypes. major trials leading registration approved targeted agents, patients stratified according imdc risk model (see chapter 6.6 prognostic models) . 7.4.2.1. tyrosine kinase inhibitors 7.4.2.1.1. sunitinib sunitinib oral tki inhibitor anti-tumour anti-angiogenic activity. first-line monotherapy sunitinib demonstrated significantly longer pfs compared ifn-α. overall survival greater patients treated sunitinib (26.4 months) vs. ifn-α (21.8 months) despite crossover . effect trial, sunitinib 50 mg/day (four weeks on/two weeks off) compared continuous uninterrupted sunitinib 37.5 mg/day patients clear cell metastatic renal cell carcinoma (cc-mrcc) . significant differences os seen (23.1 vs. 23.5 months, p = 0.615). toxicity comparable arms. non-significant, numerically longer time progression standard 50 mg dosage, authors recommended using regimen. alternate scheduling sunitinib (two weeks on/one week off) used manage toxicity, robust data support use lacking . 7.4.2.1.2. pazopanib pazopanib oral angiogenesis inhibitor. trial pazopanib vs. placebo treatment-naive mrcc patients cytokine-treated patients, significant improvement pfs tumour response observed . non-inferiority trial comparing pazopanib sunitinib (comparz) established pazopanib alternative sunitinib. showed pazopanib associated significantly worse pfs os compared sunitinib. two drugs different toxicity profiles, qol better pazopanib pazopanib . another patient-preference study (pisces), patients preferred pazopanib sunitinib (70% vs. 22%, p < 0.05) due symptomatic toxicity . studies limited intermittent therapy (sunitinib) compared continuous therapy (pazopanib). 7.4.2.1.3. axitinib axitinib oral selective second-generation inhibitor vegfr-1, -2, -3. axitinib first evaluated second-line treatment. axis trial, axitinib compared sorafenib patients previously failed cytokine treatment targeted agents (mainly sunitinib) . overall median pfs greater axitinib sorafenib. axitinib associated greater pfs sorafenib (4.8 vs. 3.4 months) progression sunitinib. axitinib showed grade 3 diarrhoea 11%, hypertension 16%, fatigue 11% patients. final analysis os showed significant differences axitinib sorafenib . randomised phase iii trial axitinib vs. sorafenib first-line treatment-naive cc-mrcc, significant difference median pfs treatment groups demonstrated, although study underpowered, raising possibility type ii error . result study, axitinib approved first-line therapy. 7.4.2.1.4. cabozantinib cabozantinib oral inhibitor tyrosine kinase, including met, vegf axl. cabozantinib investigated phase study patients resistant vegfr mtor inhibitors demonstrating objective responses disease control . based results rct investigated cabozantinib vs. everolimus patients ccrcc failing one vegf-targeted therapies (meteor) . cabozantinib delayed pfs compared everolimus vegf-targeted therapy refractory disease (hr: 0.58, 95% ci: 0.45-0.75) (le: 1b). median os 21.4 months (95% ci: 18.7 estimable) cabozantinib 16.5 months (95% ci: 14.7-18.8) everolimus vegf-resistant rcc. hr death 0.66 (95% ci: 0.53-0.83, p = 0.0003) . grade iii iv adverse events reported 74% cabozantinib 65% everolimus. adverse events managed dose reductions; doses reduced 60% patients received cabozantinib. alliance a031203 cabosun randomised phase ii trial comparing cabozantinib sunitinib first-line 157 intermediate- poor-risk patients favoured cabozantinib rr pfs, os . cabozantinib significantly increased median pfs (8.2 vs. 5.6 months, adjusted hr: 0.66, 95% ci: 0.46 0.95; one-sided p = 0.012). objective response rate 46% (95% ci: 34-57) cabozantinib vs. 18% (95% ci: 10-28) sunitinib. all-causality grade iii iv adverse events similar cabozantinib sunitinib. difference os seen. due limitations statistical analyses within trial, evidence inferior existing choices. 7.4.2.1.5. lenvatinib lenvatinib oral multi-target tki vegfr1, vegfr2, vegfr3, inhibitory activity fibroblast growth factor receptors (fgfr1, fgfr2, fgfr3, fgfr4), platelet growth factor receptor (pdgfrα), re-arranged transfection (ret) receptor stem cell factor (kit). recently investigated randomised phase ii study combination everolimus vs. lenvatinib everolimus alone (see section 7.4.4.1.1 discussion results) . 7.4.2.1.6. tivozanib tivozanib potent selective tki vegfr1, vegfr2, vegfr3 compared two phase iii trials sorafenib patients mrcc . tivozanib approved ema front-line mrcc. associated pfs advantage studies, os advantage seen. view choice sorafenib control arm front-line trial, panel considers much uncertainty, many attractive alternatives, support use front-line setting. 7.4.2.2. monoclonal vegf antibody bevacizumab humanised monoclonal antibody. initial first-line treatment combination ifn-α superseded effective therapies [551-553]. bevacizumab combination atezolizumab approved treatment mrcc (see section 7.4.3.2) . 7.4.2.3.mtor inhibitors 7.4.2.3.1. temsirolimus temsirolimus specific inhibitor mtor . use superseded front-line treatment option. 7.4.2.3.2. everolimus everolimus oral mtor inhibitor, established treatment vegf-refractory disease. record-1 study compared everolimus plus best supportive care (bsc) vs. placebo plus bsc patients previously failed anti-vegfr treatment (or previously intolerant vegf-targeted therapy) . data showed median pfs 4 vs. 1.9 months everolimus placebo, respectively . panel consider, even absence conclusive data, everolimus may present therapeutic option patients intolerant to, previously failed, immune- vegfr-targeted therapies (le: 4). recent phase ii data suggest adding lenvatinib attractive. 7.4.2.4. small molucule inhibitor 7.4.2.4.1. belzutifan belzutifan inhibitor hif2a transcription factor single agent activity ccrcc. initial phase i/ii trials 55 patients confirmed objective response rate 25% (all partial responses), median progression-free survival 14.5 months. common grade ≥3 adverse events anemia (27%) hypoxia (16%) . randomised phase iii litespark 005, shows progression free survival advantage everolimus heavily pretreated ccrcc. favorable adverse event profile. considered attractive alternative everolimus setting. overall survival awaited results number combination studies . 7.4.2.5. vascular endothelial growth factor (vegf) targeted therapy intermittent vegf targeted therapy attractive patients long term therapy, due chronic toxicity associated long term therapy fatigue. tested sunitinib pazopainib phase iii study found safe . patients study stable disease (or better) least six months staring therapy. closely followed progression cross sectional imaging. cessation therapy associated higher rates progression detrimental effect seen os . intermittent therapy tested vefg/pd-1 combinations, therefore application modern 1st line setting unknown, extrapolation suggests safe. 7.4.2.6. summary evidence recommendations single-agent targeted therapy metastaticclear-cell rcc summary evidencelesingle-agent vegf-targeted therapy superseded immune checkpoint-based combination therapy.1bintermittent vegf therapy considered patients long term vegf targeted therapy2io-vegfr tki combination estblished rr pfs benefot single agent vegfr tki os benefit subgroup analysis.1apazopanib non-inferior sunitinib first-line management option mrcc.1bcabozantinib intermediate- poor-risk treatment-naive ccrcc leads better response rates pfs os compared sunitinib.2btivozanib ema approved first-line setting.3single-agent vegf-targeted therapies preferentially recommended first-line pd-l1-based combinations. re-challenge treatments already used avoided.3single-agent cabozantinib nivolumab superior everolimus one lines vegf-targeted therapy.1beverolimus prolongs pfs vegf-targeted therapy compared placebo. longer widely recommended third-line therapy.1bbelzutifan progression free survial advantage everolimus second lines pretreated clear cell renal cancer.1blenvatinib combination everolimus improved pfs everolimus alone vegf-refractory disease. role icis uncertain. lack robust data combination making recommendation challenging.2a recommendationsstrength ratingoffer nivolumab cabozantinib immune checkpoint inhibitor-naive vascular endothelial growth factor receptor (vegfr)-refractory clear-cell metastatic renal cell carcinoma (cc-mrcc) one two lines therapy.strongsequencing agent used second-line therapy (nivolumab cabozantinib) third-line therapy recommended.weakoffer vegf-tyrosine kinase inhibitors second-line therapy patients refractory nivolumab plus ipilimumab axitinib plus pembrolizumab cabozantinib plus nivolumab lenvatinib plus pembrolizumab.weakoffer cabozantinib vegf-targeted therapy cc-mrcc.strongsequence systemic therapy treating mrcc.strongoffer immune checkpoint inhibitor combination therapy advanced cc-mrcc sarcomatoid features.weakoffer belzutifan alternative everolimus patients previously treated second fourth line therapy clear cell renal carcinoma.weakintermittent single agent vegfr tyrosine kinase inhibitor offered case partial response stable disease > 6 months.weak